<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331848</url>
  </required_header>
  <id_info>
    <org_study_id>PXT-CL17-003</org_study_id>
    <nct_id>NCT03331848</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)</brief_title>
  <acronym>ATTUNED</acronym>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prexton Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prexton Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa
      proof of concept in subjects with PD treated with a stable dose of levodopa who are
      experiencing Motor Complications of Levodopa Therapy
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business reasons
  </why_stopped>
  <start_date type="Anticipated">January 15, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Unified Dyskinesia Rating Scale (UDysRS) total score in subjects with PD experiencing levodopa-induced dyskinesia.</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT002331 - 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>BID</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT002331 - 20mg</intervention_name>
    <description>Oral</description>
    <arm_group_label>PXT002331 - 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 35 and 85 years of age, inclusive, at the time of signing informed consent

          -  Diagnosed after the age of 30 years with idiopathic PD

          -  A documented medical history of idiopathic PD for at least 3 years

          -  Disease severity of 2 to 4 on the modified Hoehn and Yahr scale when in the OFF state

          -  Been treated with a stable regimen of levodopa-containing therapy

          -  Subjects must be receiving at least 3 doses per day of levodopa-containing therapy,
             and must be on a stable dose for at least 2 weeks for immediate-release levodopa or at
             least 6 weeks for prolonged-release levodopa preparations prior to the first screening
             visit

          -  Experienced LID over a period of at least 3 months prior to randomization

          -  If needed, in the opinion of the investigator, subjects must have a caregiver

          -  Female subjects will be women of non-childbearing potential

        Exclusion Criteria:

          -  Patient is currently participating in or has participated in another study in the last
             3 months

          -  Subjects with atypical, secondary, or drug-induced Parkinsonism

          -  Subjects with a history of dyskinesia that was exclusively diphasic, OFF state,
             myoclonic, dystonic, or akathetic without peak-dose dyskinesia

          -  Subjects with a MoCA score of &lt;25

          -  Subjects who have, or who had a history of, any clinically significant hepatic or
             gallbladder disorder, as determined by the investigator

          -  Subjects who have dementia, currently active psychosis, or hallucinations.

          -  Suicide attempt within 1 year prior to the first screening visit, or severe suicidal
             ideation within 6 months prior to the first screening visit

          -  Subject has a current diagnosis of epilepsy,

          -  Any known contraindication to the use of levodopa, including a history of malignant
             melanoma or a history of narrow-angle glaucoma

          -  Carcinoma or successfully treated squamous cell carcinoma of the skin and no sing of
             disease recurrence for at least 5 years

          -  Subjects who have had a clinically significant illness within 4 weeks before the first
             dose, as determined by the investigator

          -  Subjects with scheduled surgeries/hospitalizations during the study period

          -  Any advanced, severe, or unstable disease (other than PD) that may interfere with the
             primary and secondary study outcome evaluations

          -  Subjects who have undergone prior neurosurgical operation for PD,

          -  Subjects currently taking (or expected to be administered during the course of the
             study) any of the prohibited medications (amantadine, safinamide,
             dopamine-antagonists).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levodopa-Induced Dyskinesia (LID)</keyword>
  <keyword>Foliglurax</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>mGlu4 PAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

